Enterprise Value
482.5M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
11.89%
Insider Ownership
1.31%
Institutional Own.
36.82%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SP-102 (SEMDEXA™) Details Sciatica , Spine disorder | NDA FDA meeting | |
STI-5656 (Abivertinib Maleate) (BTK and EGFR inhibitor) Details NSCLC (Non small-cell lung carcinoma) | Phase 3 Data readout | |
OVYDSO (STI-1558) Details COVID-19 | Phase 3 Initiation | |
COVI-MSC (STI-8282) (CoronaStem1) Details ARDS (Acute respiratory distress syndrome) associated with COVID-19 | Phase 2 Data readout | |
SP-103 Details Acute Low Back Pain | Phase 2 Data readout | |
COVI-DROPS Details COVID-19 | Phase 2 Data readout | |
STI-1499 (COVIGUARD™) Details COVID-19 | Phase 1 Data readout | |
Failed Discontinued | ||
Failed Discontinued | ||
Abivertinib Maleate (Fujovee) (STI-5656) (BTK inhibitor) Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Failed Discontinued | |
STI-3031 (anti-Pd-L1 antibody) Details Urothelial cancer, Cancer | Failed Discontinued | |
STI-2020 (COVI-AMG) Details COVID-19, Solid tumor/s | Failed Discontinued |